RecruitingPhase 1Phase 2NCT06108063

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan


Sponsor

Steadman Philippon Research Institute

Enrollment

120 participants

Start Date

Mar 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Losartan and a drug called Placebo - Losartan for people with knee arthroplasty, total. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLosartan

12.5 mg oral Losartan taken for 28 days total (4 week postoperative).

DRUGPlacebo - Losartan

Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).


Locations(1)

The Steadman Clinic

Vail, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06108063


Related Trials